Sex Difference Leads to Differential Gene Expression Patterns and Therapeutic Efficacy in Mucopolysaccharidosis IVA Murine Model Receiving AAV8 Gene Therapy

• Published in: International journal of molecular sciences Vol. 23; no. 20; p. 12693
• Main Authors: Piechnik, Matthew, Amendum, Paige C, Sawamoto, Kazuki, Stapleton, Molly, Khan, Shaukat, Fnu, Nidhi, Álvarez, Victor, Pachon, Angelica Maria Herreño, Danos, Olivier, Bruder, Joseph T, Karumuthil-Melethil, Subha, Tomatsu, Shunji
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.10.2022; MDPI
• Subjects: adeno-associated virus; Animal models; Animals; Antibodies, Neutralizing - therapeutic use; Antibody response; Capsid Proteins - genetics; Cartilage; Cartilage (articular); Chondroitinsulfatases - genetics; Cytomegalovirus; Disease Models, Animal; Enzymatic activity; Enzyme activity; Enzymes; Female; Females; Femur; Gender differences; Gene Expression; Gene therapy; Genetic disorders; Genetic Therapy; Globulins; Growth plate; Histology; Humans; Immune response; Immune system; Immunogenicity; Infectious diseases; Liver; Male; Males; Metabolic disorders; Metabolism; Mice; Mucopolysaccharidoses; Mucopolysaccharidosis; Mucopolysaccharidosis IV; N-Acetylgalactosamine; Pathology; Rodents; Sex Characteristics; Sex determination; Sex differences; Thyroxine; Thyroxine-Binding Globulin - genetics; Thyroxine-Binding Globulin - metabolism; Vectors (Biology); Viral infections; Womens health; mucopolysaccharidoses; immune response; adeno-associated virus
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232012693

Adeno-associated virus (AAV) vector-based therapies can effectively correct some disease pathology in murine models with mucopolysaccharidoses. However, immunogenicity can limit therapeutic effect as immune responses target capsid proteins, transduced cells, and gene therapy products, ultimately resulting in loss of enzyme activity. Inherent differences in male versus female immune response can significantly impact AAV gene transfer. We aim to investigate sex differences in the immune response to AAV gene therapies in mice with mucopolysaccharidosis IVA (MPS IVA). MPS IVA mice, treated with different AAV vectors expressing human N-acetylgalactosamine 6-sulfate sulfatase (GALNS), demonstrated a more robust antibody response in female mice resulting in subsequent decreased GALNS enzyme activity and less therapeutic efficacy in tissue pathology relative to male mice. Under thyroxine-binding globulin promoter, neutralizing antibody titers in female mice were approximately 4.6-fold higher than in male mice, with GALNS enzyme activity levels approximately 6.8-fold lower. Overall, male mice treated with AAV-based gene therapy showed pathological improvement in the femur and tibial growth plates, ligaments, and articular cartilage as determined by contrasting differences in pathology scores compared to females. Cardiac histology revealed a failure to normalize vacuolation in females, in contrast, to complete correction in male mice. These findings promote the need for further determination of sex-based differences in response to AAV-mediated gene therapy related to developing treatments for MPS IVA.